NFL Biosciences (XPAR:ALNFL) Change In Receivables : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences Change In Receivables?

NFL Biosciences's change in receivables for the quarter that ended in Dec. 2023 was €0.00 Mil. It means NFL Biosciences's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

NFL Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means NFL Biosciences's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

NFL Biosciences's Accounts Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NFL Biosciences's liquidation value for the six months ended in Dec. 2023 was €-1.09 Mil.

NFL Biosciences Change In Receivables Historical Data

The historical data trend for NFL Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NFL Biosciences Change In Receivables Chart

NFL Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

NFL Biosciences Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

NFL Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

NFL Biosciences (XPAR:ALNFL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

NFL Biosciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, NFL Biosciences's accounts receivable are only considered to be worth 75% of book value:

NFL Biosciences's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.529	-	3.621	+	0.75 * 0	+	0.5 * 0
=	-1.09

NFL Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of NFL Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

NFL Biosciences (XPAR:ALNFL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

82F:Germany

Address

199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170

Website

https://www.nflbiosciences.com/

NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (XPAR:ALNFL) Headlines

No Headlines